Introduction
Over the past 25 years, T-cell therapies have transformed cancer treatment, especially with the emergence of CAR-T cells. However, another subset of T cells, the **gamma delta (γδ) T cells**, is gaining attention for its potential to fight cancer. Unlike the more familiar alpha beta (αβ) T cells, **γδ T cells** offer unique advantages that make them a promising candidate in the field of cancer immunotherapy. Companies like Cytomed are already developing γδ T-cell therapeutics.
What are Gamma Delta T Cells?
T cells are divided into two categories: **αβ T cells** and **γδ T cells**. The latter possess a T-cell receptor (TCR) composed of **γ** and **δ chains**, setting them apart from αβ T cells, which have **α** and **β chains**. γδ T cells, although only comprising about 4% of human peripheral blood, play a crucial role in bridging the **innate and adaptive immune responses**. Their diverse functionalities and distinct characteristics make them key players in **immune surveillance** and cancer defense.
Gamma Delta T Cells in the Blood
γδ T cells can be further classified into **Vδ2 T cells** and **non-Vδ2 T cells**, based on the expression of the TCR delta chain. The **Vγ9Vδ2 T cells**, found in high percentages in human blood, are critical in recognizing phosphoantigens (PAgs) produced by microorganisms and tumor cells. These cells serve as innate-like defenders, capable of rapid immune responses without needing to wait for specific antigen presentation.
Why are Gamma Delta T Cells Unique?
Gamma delta T cells are equipped with several key receptors, including the **T-cell receptor, NK receptor**, and **Fc receptor**. These receptors allow γδ T cells to:
1. **Detect antigens** associated with tumors.
2. **Differentiate** between normal and cancerous cells.
3. **Enhance immune activity** through interactions with therapeutic antibodies, amplifying tumor destruction.
These properties make γδ T cells highly effective in identifying and killing cancer cells while minimizing damage to healthy tissues.
The Manufacturing Process of Gamma Delta T Cells
**1. Collection of Source Material:** Peripheral blood mononuclear cells (PBMCs) are collected from either a healthy donor or the patient.
**2. Isolation of γδ T Cells:** Specific markers are used to isolate γδ T cells from the PBMCs.
**3. Activation and Expansion:** γδ T cells are activated with stimulants like zoledronic acid and expanded ex vivo with cytokines such as IL-2.
**4. Genetic Modification:** In some therapies, γδ T cells may be genetically modified to boost their anti-tumor capabilities.
**5. Quality Control:** Rigorous testing ensures the safety, potency, and effectiveness of the cells.
**6. Cryopreservation:** The final cell product is frozen for storage and transport before infusion into the patient.
Mechanism of Action
γδ T cells can recognize and kill tumor cells through several mechanisms:
- **Direct cytotoxicity:** They release cytotoxic granules (perforin and granzymes) to induce tumor cell apoptosis.
- **Cytokine production:** γδ T cells secrete cytokines like **IFN-γ** and **TNF-α**, which recruit other immune cells and inhibit tumor growth.
- **Stress Antigen Recognition:** These cells recognize stress-induced antigens like **MICA/MICB**, often overexpressed on tumor cells.
Advantages of Gamma Delta T-Cell Therapy
- **Broad Target Recognition:** Unlike αβ T cells, γδ T cells do not rely on MHC molecules, making them capable of targeting a wide range of cancer types.
- **Rapid Response:** As innate-like immune cells, they respond more quickly than αβ T cells.
- **Low Risk of Graft-versus-Host Disease (GvHD):** This makes γδ T cells ideal for allogeneic therapies.
- **Synergistic Potential:** They can be combined with other treatments, such as checkpoint inhibitors or monoclonal antibodies, for enhanced efficacy.
Clinical Applications and Research
- **Hematologic Malignancies:** γδ T cells show potential in treating blood cancers like leukemia and lymphoma.
- **Solid Tumors:** Research is ongoing to enhance the efficacy of γδ T cells in solid tumors such as lung, breast, and prostate cancers.
- **Combination Therapies:** Pairing γδ T cells with immunotherapies like checkpoint inhibitors has shown promising results.
Challenges and Future Directions
While promising, γδ T cell therapy faces several challenges:
- **Expansion and Activation:** Achieving optimal ex vivo expansion of γδ T cells remains a key area of research.
- **Target Specificity:** Ensuring γδ T cells effectively home to tumors and avoid healthy tissue is vital.
- **Tumor Microenvironment:** The immunosuppressive environment of tumors can reduce the efficacy of γδ T cells. Solutions to overcome this are being studied.
Conclusion
Gamma delta T cell therapy is emerging as a powerful new tool in the fight against cancer. With their unique properties—broad antigen recognition, rapid immune response, and low GvHD risk—γδ T cells are poised to become a key player in immunotherapy. As clinical trials and research progress, γδ T cells could offer new hope for patients, particularly those with cancers resistant to conventional treatments.
---
